Anti-Beta 2-Glycoprotein I Antibody Isotype and IgG Subclass in Antiphospholipid Syndrome Patients

References

• Hughes G. R., Harris N. N., Gharavi A. E. The anti-cardiolipin syndrome. J. Rheumatol 1986; 13(3)486–9
   PubMedGoogle Scholar
• Asherson R. A. A “primary” antiphospholipid syndrome?. J. Rheumatol 1988; 15(12)1742–6
   PubMed Web of Science ®Google Scholar
• Hughes G. R. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341–4
   PubMed Web of Science ®Google Scholar
• Harris E. N., Chan J. K.H., Asherson R. A., Aber V. R., Gharavi A. E., Hughes G. R.V. Thrombosis, recurrent fetal loss and thrombocytopenia. Arch. Intern. Med 1986; 146: 2153–6
   PubMedGoogle Scholar
• Loizou S., Cofiner C., Weetman A. P., Walport M. J. Immunoglobulin class and IgG subclass distribution of anlicardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin. Exp. Immunol 1992; 90: 434–9
   PubMed Web of Science ®Google Scholar
• Tsutsumi A., Matsuura E., Ichikawa K., Fujisaku A., Mukai M., Kobayashi S., Koike T. Antibodies to beta 2-glycoprotein 1 and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39(9)1466–74
   PubMedGoogle Scholar
• Gharavi A. E., Harris E. N., Asherson R. A., Hughes G. R. Anlicardiolipin antibodies: isotypc distribution and phospholipid specificity. Aim. Rheum Dis 1987; 46(1)1–6
   PubMed Web of Science ®Google Scholar
• Loizou S. A., Walport M. J., Davies K. A. The anti-phospholipid syndrome in infectious diseases. The Anti-phospholipid Syndrome. CRC Press, Inc., New York 1996; 267–84
   Google Scholar
• Gharavi A. E., Harris E. N., Lockshin M. D., Hughes G. R.V., Elkon B. K. IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies in systemic lupus erythematosus. Ann. Rheum. Dis 1988; 47: 286–90
   PubMed Web of Science ®Google Scholar
• Levy R. A., Gharavi A. E., Sammaritano L. R., Habina L., Qamar T., Lockshin M. D. Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. J. Rheumatol 1990; 17: 1036–41
   PubMedGoogle Scholar
• Tsutsumi A., Koike T., lchikawa K., Shimada K., Takabayashi K., Tomioka H., Yoshida S. IgG subclasses distribution of anticardiolipin antibody in patients with systemic lupus erythematosus. J. Rheumatol 1988; 15: 1764–7
   PubMedGoogle Scholar
• Sammaritano L. R., Ng S., Sobel R., Lo S. K., Simantov R., Furie R., Kaell A., Silverstein R., Salmon J. E. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum 1997; 40(11)1998–2006
   PubMedGoogle Scholar
• Matsuura E., Igarashi M., Igarashi Y., Nagae H., lchikawa K., Yasuda T., Koike T. Molecular definition of human β2-glycoprotein 1 (β-GPl) by cDNA cloning and interspecies differences of β2-GP1 in alternation of anticardiolipin binding. Int. Immunol 1991; 3(12)1217–21
   PubMed Web of Science ®Google Scholar
• Arvieux J., Roussel B., Jacob M. C., Colomb M. G. Measurement of anti-phospholipid antibodies by EL1SA using beta 2-glycoprotein I as an antigen. J. Immunol. Methods 1991; 143(2)223–9
   PubMedGoogle Scholar
• Viard J. P., Amount Z., Bach J. F. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am. J. Med 1992; 93(2)181–6
   PubMedGoogle Scholar
• McNally T., Mackie I. J., Machin S. J., Isenberg D. A. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br. J. Rheumatol 1995; 34(11)1031–6
   PubMedGoogle Scholar
• Martinuzzo M. E., Forastiero R. R., Carreras L. O. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis. Br. J. Haematol 1995; 89(2)397–402
   PubMedGoogle Scholar
• Balestrieri G., Tincani A., Spatola L., Allegri F., Prati E., Cattaneo R., Valesini G., Del Papa N., Meroni P. Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?. Lupus 1995; 4(2)122–30
   PubMed Web of Science ®Google Scholar
• Guerin J., Feighery C., Sim R. B., Jackson J. Antibodies to beta 2-glycoprotein I - a specific marker for the antiphospholipid syndrome. Clin. Exp. Immunol 1997; 109(2)304–9
   PubMedGoogle Scholar
• McNally T., Purdy G., Mackie I. J., Machin S. J., Isenberg D. A. The use of an anti-b2-glycoprotein 1 assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br. J. Haematol 1995; 91: 471–3
   PubMedGoogle Scholar
• Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome. J. Rheumatol 1992; 19: 1778–81
   PubMed Web of Science ®Google Scholar
• Tan E., Cohen A., Fries J., Masi A., McShane D., Rothfield N., Schaller J., Talal N., Winchester R. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–77
   PubMed Web of Science ®Google Scholar
• Cabral A. R., Cabiedes J., Alarcon-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J. Rheumatol 1995; 22(10)1894–8
   PubMedGoogle Scholar
• Fanopoulos D., Teodorescu M. R., Varga J., Teodorescu M. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J. Rheumatol 1998; 25(4)675–80
   PubMed Web of Science ®Google Scholar
• Love P. E., Santoro S. A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann. Intern. Med 1990; 112: 682–98
   PubMed Web of Science ®Google Scholar
• Arvieux J., Roussel B., Ponard D., Colomb M. G. IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients. Clin. Exp. Immunol 1994; 95(2)310–15
   PubMedGoogle Scholar
• Pierangeli S. S., Harris E. N. Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human β-glycoprotein 1 or anticardiolipin antibodies alone. Clin. Exp. Immunol 1993; 93: 269–72
   PubMedGoogle Scholar
• Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., Allegri F., Balestrieri G., Valesini G., Shoenfeld Y. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J. Autoimmunity 1994; 7(4)441–55
   PubMedGoogle Scholar
• Shoenfeld Y., Ziporen L. Lessons from experimental APS models. Lupus 1998; 7(Suppl. 2)S158–61
   Google Scholar
• Atsumi T., Caliz R., Amengual O., Khamashta M. A., Hughes G. R. Fcgamma receptor HA H/RI31 polymorphism in patients with antiphospholipid antibodies. Thromb. Haemost 1998; 79(5)924–7
   PubMedGoogle Scholar